吗氯贝胺：演变、药效学及药代动力学特性
Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.
作者信息
Bonnet Udo
机构信息
Rheinische Kliniken Essen, Department of Psychiatry and Psycotherapy, University of Essen, Essen, Germany.
出版信息
CNS Drug Rev. 2002 Fall;8(3):283-308. doi: 10.1111/j.1527-3458.2002.tb00229.x.
Abstract
The benzamide moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA). It has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively in anxiety disorders. While clinical aspects will be presented in a subsequent review, this article focuses primarily on moclobemide's evolution, pharmacodynamic and pharmacokinetic properties. In particular, the effects on neurotransmission and intracellular signal transduction, the neuroendocrine system, the tyramine pressure response and animal models of depression are surveyed. In addition, other CNS effects are reviewed with special respect to experimental serotonergic syndrome, anxiolytic and antinociceptive activity, sleep, cognition and driving performance, neuroprotection and seizures.
摘要
苯甲酰胺类药物吗氯贝胺是一种单胺氧化酶-A（RIMA）的可逆抑制剂。它已在多种抑郁症治疗中得到广泛评估，而在焦虑症治疗中的评估则相对较少。虽然临床方面将在后续综述中阐述，但本文主要关注吗氯贝胺的发展历程、药效学和药代动力学特性。特别对其在神经传递、细胞内信号转导、神经内分泌系统、酪胺升压反应及抑郁症动物模型等方面的作用进行了研究探讨。此外，还对其他中枢神经系统效应进行了综述，尤其涉及实验性血清素综合征、抗焦虑和抗伤害感受活性、睡眠、认知与驾驶性能、神经保护及癫痫发作等方面。
相似文献
1
Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.吗氯贝胺：演变、药效学及药代动力学特性
CNS Drug Rev. 2002 Fall;8(3):283-308. doi: 10.1111/j.1527-3458.2002.tb00229.x.
2
Moclobemide: therapeutic use and clinical studies.吗氯贝胺：治疗用途及临床研究。
CNS Drug Rev. 2003 Spring;9(1):97-140. doi: 10.1111/j.1527-3458.2003.tb00245.x.
3
Moclobemide in patients with dementia and depression.
Adv Neurol. 1999;80:509-19.
4
[Moclobemide].[吗氯贝胺]
Dtsch Med Wochenschr. 1995 Aug 25;120(34-35):1175-6. doi: 10.1055/s-0029-1234212.
5
A risk-benefit assessment of moclobemide in the treatment of depressive disorders.吗氯贝胺治疗抑郁症的风险效益评估。
Drug Saf. 1995 Jan;12(1):46-54. doi: 10.2165/00002018-199512010-00004.
6
[Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].[精神医学中的单胺氧化酶抑制剂。当前知识状况]
Nervenarzt. 1996 May;67(5):339-47.
7
RIMA: a safe concept in the treatment of depression with moclobemide.RIMA：用吗氯贝胺治疗抑郁症的一种安全理念。
Can J Psychiatry. 1992 Sep;37 Suppl 1:7-11.
8
Evaluation of single-point sampling strategies for the estimation of moclobemide exposure in depressive patients.评估单点采样策略以估算抑郁患者吗氯贝胺的暴露量。
J Clin Pharmacol. 2011 May;51(5):661-71. doi: 10.1177/0091270010372105. Epub 2010 May 21.
9
[Aurorix--an antidepressant with a wide spectrum of action].
Voen Med Zh. 1998 Apr;319(4):50-2.
10
Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.从三环类抗抑郁药转换为吗氯贝胺治疗：新一代单胺氧化酶抑制剂。
J Clin Psychopharmacol. 1995 Feb;15(1):41-8. doi: 10.1097/00004714-199502000-00007.
引用本文的文献
1
Impact of COVID- 19 pandemic on antidepressants consumptions by wastewater analysis in Turkey.土耳其通过污水分析评估新冠疫情对抗抑郁药消费的影响。
Sci Total Environ. 2022 Sep 10;838(Pt 2):155916. doi: 10.1016/j.scitotenv.2022.155916. Epub 2022 May 12.
2
Palladium nanoparticles on a pyridinium supported ionic liquid phase: a recyclable and low-leaching palladium catalyst for aminocarbonylation reactions.吡啶鎓负载离子液体相上的钯纳米颗粒：一种用于氨基羰基化反应的可循环且低浸出的钯催化剂。
RSC Adv. 2020 Jun 23;10(40):23988-23998. doi: 10.1039/d0ra03406a. eCollection 2020 Jun 19.
3
Novel Pharmacological Approaches to the Treatment of Depression.治疗抑郁症的新型药理学方法
Life (Basel). 2022 Jan 28;12(2):196. doi: 10.3390/life12020196.
4
Synthesis and Biological Evaluation of Dantrolene-Like Hydrazide and Hydrazone Analogues as Multitarget Agents for Neurodegenerative Diseases.丹曲林类似物的酰腙和腙类衍生物的合成及生物评价作为神经退行性疾病的多靶标药物。
ChemMedChem. 2021 Sep 16;16(18):2807-2816. doi: 10.1002/cmdc.202100209. Epub 2021 Jun 22.
5
Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments.大脑中的忧郁症：重度抑郁症的分子基础以及相关的药理学和非药理学治疗方法。
Genes (Basel). 2020 Sep 18;11(9):1089. doi: 10.3390/genes11091089.
6
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.吗氯贝胺抑制单胺氧化酶 A 增强 MPTP 损毁恒河猴模型中 L-DOPA 的抗帕金森作用。
Naunyn Schmiedebergs Arch Pharmacol. 2020 Nov;393(11):2157-2164. doi: 10.1007/s00210-020-01933-y. Epub 2020 Jul 3.
7
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.单胺氧化酶 A 抑制作为单一疗法可逆转 MPTP 损伤的狨猴帕金森病。
Naunyn Schmiedebergs Arch Pharmacol. 2020 Nov;393(11):2139-2144. doi: 10.1007/s00210-020-01927-w. Epub 2020 Jun 29.
8
A Prospective Repurposing of Dantrolene as a Multitarget Agent for Alzheimer's Disease.丹曲林钠作为阿尔茨海默病多靶药物的前瞻性再利用。
Molecules. 2019 Nov 25;24(23):4298. doi: 10.3390/molecules24234298.
9
Kinetics, mechanism, and inhibition of monoamine oxidase.单胺氧化酶的动力学、机制和抑制作用。
J Neural Transm (Vienna). 2018 Nov;125(11):1659-1683. doi: 10.1007/s00702-018-1861-9. Epub 2018 Mar 7.
10
Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.辅助性缓释5-羟色氨酸治疗难治性抑郁症：临床及临床前理论依据
Trends Pharmacol Sci. 2016 Nov;37(11):933-944. doi: 10.1016/j.tips.2016.09.001. Epub 2016 Sep 28.
本文引用的文献
1
Hydrazine derivatives of isonicotinic acid (rimifon marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis; a preliminary report.异烟酸肼衍生物（雷米封、异烟酰胺）治疗进展期活动性干酪性肺炎型肺结核的初步报告
Am Rev Tuberc. 1952 Apr;65(4):402-28. doi: 10.1164/art.1952.65.4.402.
2
Desmethylimipramine, a new type of antidepressant drug.
Med Exp Int J Exp Med. 1961;5:454-8. doi: 10.1159/000135120.
3
Iproniazid (marsilid) phosphate, a therapeutic agent for mental disorders and debilitating diseases.
Psychiatr Res Rep Am Psychiatr Assoc. 1957 Dec;8:142-52.
4
Moclobemide: therapeutic use and clinical studies.吗氯贝胺：治疗用途及临床研究。
CNS Drug Rev. 2003 Spring;9(1):97-140. doi: 10.1111/j.1527-3458.2003.tb00245.x.
5
Valproate acidifies hippocampal CA3-neurons--a novel mode of action.
Eur Neuropsychopharmacol. 2002 Aug;12(4):279-85. doi: 10.1016/s0924-977x(02)00023-8.
6
High-performance liquid chromatography-electrospray ionization mass spectrometry method for the measurement of moclobemide and two metabolites in plasma.用于测定血浆中吗氯贝胺及其两种代谢物的高效液相色谱-电喷雾电离质谱法
J Chromatogr B Biomed Sci Appl. 2001 Apr 25;754(2):319-26. doi: 10.1016/s0378-4347(00)00625-3.
7
Effects of the monoamine oxidase A inhibitor moclobemide on hippocampal plasticity in GR-impaired transgenic mice.
J Psychiatr Res. 2001 Jan-Feb;35(1):29-42. doi: 10.1016/s0022-3956(00)00040-6.
8
Mitochondrial dysfunction in bipolar disorder.双相情感障碍中的线粒体功能障碍。
Bipolar Disord. 2000 Sep;2(3 Pt 1):180-90. doi: 10.1034/j.1399-5618.2000.020305.x.
9
The mitochondrial hypothesis of bipolar disorder.
Bipolar Disord. 2000 Sep;2(3 Pt 1):145-7. doi: 10.1034/j.1399-5618.2000.020301.x.
10
Moclobemide reduces intracellular pH and neuronal activity of CA3 neurones in guinea-pig hippocampal slices-implication for its neuroprotective properties.吗氯贝胺降低豚鼠海马切片中CA3神经元的细胞内pH值和神经元活性——对其神经保护特性的启示。
Neuropharmacology. 2000 Aug 23;39(11):2067-74. doi: 10.1016/s0028-3908(00)00033-2.
Zotero 插件